Table 2 |
|||||
|
First-generation phase III studies of adjuvant docetaxel in breast cancer |
|||||
|
Study |
Patients |
Design |
Follow up (months) |
DFS |
OS |
|
|
|||||
|
BCIRG-001 [20] |
1,491 |
FAC × 6 versus TAC × 6 |
55 |
68% versus 75% (5-year); HR = 0.72, P = 0.001 |
81% versus 87% (5-year); HR = 0.70, P = 0.008 |
|
PACS-01 [21] |
1,999 |
FEC × 6 versus FEC × 3 → D × 3 |
60 |
73% versus 78% (5-year); HR = 0.82, P = 0.012 |
87% versus 91% (5-year); HR = 0.73, P = 0.017 |
|
ECOG 2197 [22] |
2,952 |
AC × 4 versus AD × 4 |
79.5 |
85% versus 85% (5-year); HR = 1.03, P = 0.78 |
91% versus 92% (5-year); HR = 1.06, P = 0.62 |
|
1,016 |
AC × 4 versus DC × 4 |
84 |
75% versus 81% (7-year); HR = 0.74, P = 0.033 |
82% versus 87% (7-year); HR = 0.69, P = 0.032 |
|
|
BIG 02-98 [25] |
2,887 |
A × 4 → CMF × 3 versus AC × 4 → CMF × 3 versus A × 3 → D × 3 → CMF × 3 versus AD × 4 → CMF × 3 |
62 |
D versus non-D: HR = 0.86, P = 0.051 Sequential D versus A-CMF: 78% versus 73% (5-year); HR = 0.79, P = 0.035 Concurrent AD versus AC-CMF: 74% versus 72% (5-year); HR = 0.93, P = 0.48 (NS) |
NA |
|
TAXIT 216 [26] |
972 |
E × 4 → CMF × 4 versus E × 4 → D × 4 → CMF × 4 |
54 |
HR = 0.79, P = 0.0576 |
HR = 0.72, P = 0.0797 |
|
TACT [27] |
4,162 |
FEC × 8 or E × 4 → CMF × 4 versus FEC × 4 → D × 4 |
52 |
74% versus 75% (4-year); HR = 0.97 (NS) |
82% versus 82% (4-year); HR = 0.98 (NS) |
|
GEICAM 9805 [28] |
1,059 |
FAC × 6 versus TAC × 6 |
72 |
86% versus 91% (5-year); HR = 0.66, P = 0.02 |
95% versus 97% (5-year); HR = 0.72, P = 0.27 |
|
Mavroudis et al. [29] |
756 |
FEC × 6 versus D × 4 → EC × 4 |
62.5 |
69% versus 75% (5-year); P = 0.029 |
- |
|
WSG/AGO AM02 [30] |
2,012 |
FEC × 6 versus EC × 4 → D × 4 |
46 |
85.8% versus 90.2% (5-year); HR = 1.51, P = 0.009 |
92.6% versus 94.8% (5-year); HR = 1.59, P = 0.04 |
|
|
|||||
|
First-generation phase III studies evaluating the role of docetaxel in the adjuvant treatment of breast cancer. →, followed by; A, doxorubicin; C, cyclophosphamide; D, docetaxel; DFS, disease-free survival; E, epirubicin; F, 5-fluorouracil; HR, hazard ratio; NS, not significant; OS, overall survival; TAC, docetaxel, doxorubicin, and cyclophosphamide. |
|||||
|
López-Tarruella and Martín Breast Cancer Research 2009 11:204 doi:10.1186/bcr2226 |
|||||